| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED SEPTEMBER 2022. Refer to TA824: Dexamethasone intravitreal implant for treating diabetic macular oedema |
||
|
||
Medicine details |
||
| Medicine name | dexamethasone (Ozurdex®) | |
| Formulation | intravitreal implant | |
| Reference number | 1623 | |
| Indication | Treatment of adult patients with visual impairment due to diabetic macular oedema who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy |
|
| Company | Allergan Ltd | |
| BNF chapter | Eye | |
| Assessment type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 09/01/2015 | |
| Date of issue | 13/01/2015 | |
| NICE guidance | TA824: Dexamethasone intravitreal implant for treating diabetic macular oedema |
|